New Paul Hopper Interview, page-9

Davy that is Great news
although it looks like that video is geo restricted ( unable to view it in New Zealand) your summary sounds like it sums up well what I was expecting and hoping for of IMU, that being a partnership (not a take over)
I believe a partnership with licencing will be the best fit for IMU given it is developing an ever increasing number of clinical candidates, each of could be a good fit for any number of different uses and so differant products should appeal to different pharma companies.

What this could mean for share holders:
A yearly income stream from licencing just 1 billion of sales with a 20% royalty on those sales going to Imugene would give Imugene an income of $200,000,000 then if around 20% of that was kept for further R&D which would be $40,000,000 this would see IMU management very well funded.

The remaining $160,000,000 divided between 4 billion shares ( currently there is 3.6 billion shares, but expect that number to grow to 4 billion ) would be a dividend of 4 cents per share for each 1 billion of sales.

So as the number of products and sales grow, then into the future we could easily expect sales to swell to 10 times or bigger i.e $10 billion sales (or more! and growing!) producing IMU with 2 billion per year in revenue which could give IMU the yearly ability to distribute dividends of around 40 cents per share (and growing).

fp